Company / Current Liabilities
ROCKET PHARMACEUTICALS, INC. Current Liabilities History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$30.2M
FY2025
5-year range
$22.2M / $48.5M
FY2021-FY2025
Trend
-25.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Liabilities has fluctuated over the past 8 years, ranging from $15M in FY2018 to $49M in FY2023.
Based on SEC 10-K filings.
$30M in FY2025 with a 5-year CAGR of -1.5%.
Improved from $49M to $30M over the past 2 years.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- -8.3%
- 5-Year CAGR
- -1.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -1.5%, indicating a declining trend.
- In FY2025, current liabilities decreased 25.8% year-over-year.
- Peak current liabilities was recorded in FY2023.
- Lowest current liabilities in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.68 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $30.2M | -25.8% |
| FY2024 | $40.7M | -16.1% |
| FY2023 | $48.5M | +23.8% |
| FY2022 | $39.2M | +76.7% |
| FY2021 | $22.2M | -32.0% |
| FY2020 | $32.6M | +78.1% |
| FY2019 | $18.3M | +19.1% |
| FY2018 | $15.4M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026